Insmed Inc (NASDAQ:INSM)
| 16.49 Delayed Data As of Mar 24 |  +0.05 / +0.30%Today’s Change | 16.04 Today|||52-Week Range 28.94 | -17.47% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $2.2B |
Company Description
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Contact Information
Insmed, Inc. 700 US Highway 202/206 Bridgewater New Jersey 08807-3365 |
Employees
Shareholders
| Mutual fund holders | 60.41% |
| Other institutional | 46.73% |
| Individual stakeholders | 3.41% |
Top Executives
| Will Lewis | Chairman, President & Chief Executive Officer |
| Roger Adsett | Chief Operating Officer |
| Sara M. Bonstein | Chief Financial Officer |
| Walter R. Perkins | Chief Technology Officer |
| Martina Flammer | Chief Medical Officer |
